Search Results - "Kosmider, S."

Early onset metastatic colorectal cancer in Australia by Jalali, A., Smith, S., Kim, G., Wong, H., Lee, M., Yeung, J., Loft, M., Wong, R., Shapiro, J.D., Kosmider, S., Tie, J., Ananda, S., Ma, B., Burge, M., Jennens, R., Lee, B., Johns, J., Lim, L., Dean, A., Nott, L., Gibbs, P.

“…•Colorectal cancer (CRC) incidence and mortality rates have been increasing among adults under the age of 50-years (young patients, YP) and for uncertain…”
Get full text

Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer by Jalali, A, Gard, G, Banks, S, Dunn, C, Wong, HL, Wong, R, Lee, M, Gately, L, Loft, M, Shapiro, JD, Kosmider, S, Tie, J, Ananda, S, Yeung, J M, Jennens, R, Lee, B, McKendrick, J, Lim, L, Khattak, A, Gibbs, P

“…For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This…”
Get full text

Survival impact of the Australian National Bowel Cancer Screening Programme by Ananda, S., Wong, H., Faragher, I., Jones, I. T., Steele, M., Kosmider, S., Desai, J., Tie, J., Field, K., Wong, R., Tran, B., Bae, S., Gibbs, P.

“…Background The Australian National Bowel Cancer Screening Program (NBCSP) has been offering age‐based faecal occult blood testing since 2006. With the rapid…”
Get full text

An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer by Voskoboynik, M., Bae, S., Ananda, S., Desai, J., Kosmider, S., Gibbs, P.

“…A range of treatments are available for patients with metastatic colorectal cancer (mCRC). An initial period without active treatment, a ‘watch and wait…”
Get full text

Developing a national database for metastatic colorectal cancer management: perspectives and challenges by Field, K., Wong, H.-L., Shapiro, J., Kosmider, S., Tie, J., Bae, S., Yip, D., McKendrick, J., Nott, L., Desai, J., Harold, M., Lipton, L., Stefanou, G., Lim, L., Parente, P., Gibbs, P.

“…Background The changing treatment landscape for metastatic colorectal cancer creates multiple potential treatment strategies. An Australian‐centric database…”
Get full text

Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data by Tran, B., Keating, C. L., Ananda, S. S., Kosmider, S., Jones, I., Croxford, M., Field, K. M., Carter, R. C., Gibbs, P.

“…Background/Aim:  The complexity and cost of treating cancer patients is escalating rapidly and increasingly difficult decisions are being made regarding which…”
Get full text

Linking data from hospital and cancer registry databases: should this be standard practice? by Field, K, Kosmider, S, Johns, J, Farrugia, H, Hastie, I, Croxford, M, Chapman, M, Harold, M, Murigu, N, Gibbs, P

“…Varying amounts of data related to cancer diagnosis, treatment and/or outcome are routinely collected by many disparate groups. Routinely combining data from…”
Get full text

Predictors of clinic non-attendance: opportunities to improve patient outcomes in colorectal cancer by Kosmider, S., Shedda, S., Jones, I. T., McLaughlin, S., Gibbs, P.

“…Aim: Colorectal cancer is one of the few tumour types, where routine patient follow up has been demonstrated to impact significantly on survival. Patients who…”
Get full text

Preoperative investigations for metastatic staging of colon and rectal cancer across multiple centres - what is current practice? by Kosmider, S., Stella, D. L., Field, K., Moore, M., Ananda, S., Oakman, C., Singh, M., Gibbs, P.

“…Objective  The optimal strategy for elective distant staging of colorectal carcinoma (CRC) has yet to be defined, with current guidelines based on small and…”
Get full text

Surveillance following treatment for colorectal cancer in Australia. Has best practice been adopted by medical oncologists? by Kosmider, S., Field, K., Jefford, M., Jennens, R., Gibbs, P.

“…Background:  Intensive follow up after surgery for colorectal cancer is associated with a significant survival advantage and is endorsed by expert panels, but…”
Get full text

ORIGINAL ARTICLE: Linking data from hospital and cancer registry databases: should this be standard practice? by Field, K., Kosmider, S., Johns, J., Farrugia, H., Hastie, I., Croxford, M., Chapman, M., Harold, M., Murigu, N., Gibbs, P.

“…Background: Varying amounts of data related to cancer diagnosis, treatment and/or outcome are routinely collected by many disparate groups. Routinely combining…”
Get full text

Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting by Sewak, S., Kosmider, S., Ganju, V., Woollett, A., Yeow, E. G., Le, B., Henry, M., Debrincat, M. A., Bell, R.

“…Background: Androgen ablation is the standard treatment for advanced prostate cancer. However, most patients will eventually develop progressive…”
Get full text

3052 POSTER Impact of diabetes mellitus on the development and outcomes of colorectal cancer by Gibbs, P, Murigu, N, Johns, J, Kosmider, S

Get full text

1319 Microsatellite instability in sporadic colorectal cancer: correlation with novel clinical parameters by Field, K, Tie, J, Desai, J, Lipton, L, Sieber, O, Murigu, N, Larkins, M, Kosmider, S, Gibbs, P

Get full text

P-187 Epidermal growth factor receptor inhibitors (EGFRi) in patients with left-side, RAS wildtype metastatic colorectal cancer: Clinician use and outcomes for patients by McKenzie, J., Kosmider, S., Wong, R., To, Y., Shapiro, J., Dunn, C., Burge, M., Hong, W., Caird, S., Lim, S., Wong, H., Lee, B., Gibbs, P., Wong, V.

Get full text

117P Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC) by Wong, V., McKenzie, J., Kosmider, S., Wong, R., To, Y.H., Shapiro, J., Dunn, C., Burge, M., Hong, W., Caird, S., Lim, S.H-S., Wong, H-L., Lee, B., Ma, B.B.Y., Gibbs, P.

Get full text

3066 POSTER Exploring first line chemotherapy options in metastatic colorectal cancer (mCRC): nationwide heterogeneity in patient management by Field, K, Kosmider, S, Jefford, M, Jennens, R, Green, M, Gibbs, P

Get full text

P61 Cost Utility Analysis of Circulating Tumour DNA Guided Adjuvant Chemotherapy in Stage II Colon Cancer by To, Y.H., Degeling, K., Kosmider, S., Wong, R., Lee, M., Dunn, C., Gard, G., Jalali, A., Wong, V., IJzerman, M., Gibbs, P., Tie, J.

Get full text

Compliance with TGA prescribing information - Weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer by Loft, M, Shapiro, J, Lee, M, Wong, R, Tie, J, Kosmider, S, Wong, V, Jalali, A, Lee, B, Ananda, S, Gibbs, P

“…Treatment with cetuximab provides a survival benefit for patients with RAS wild-type metastatic colorectal cancer (mCRC). Practice-defining cetuximab studies…”
Get full text

ON1 UNDERSTANDING VARIATION IN TREATMENT SEQUENCES AND OUTCOMES IN METASTATIC COLORECTAL CANCER: USING REAL WORLD DATA TO ANSWER REAL WORLD QUESTIONS by Wong, H.L., Degeling, K., Jalali, A., Shapiro, J., Kosmider, S., Wong, R., Lee, B., Burge, M., Tie, J., Yip, D., Nott, L., Khattak, A., Lim, S., Caird, S., IJzerman, M., Gibbs, P.

Get full text